Journal
FUTURE ONCOLOGY
Volume 7, Issue 12, Pages 1415-1428Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.11.124
Keywords
chemotherapy; gynecologic cancer; HDAC; HDAC inhibitor
Categories
Funding
- Georgia Cancer Coalition Distinguished Cancer Scholarship
- NIH [R01 HD 41577]
- NIH/National Cancer Institute MD Anderson Uterine Cancer SPORE
- Anderson Cancer Institute/Memorial Health University Center
- Mercer University School of Medicine
Ask authors/readers for more resources
Histone deacetylases (HDACs) remove acetyl groups from lysine residues of histones and the deacetylation allows for tighter electrostatic interactions between DNA and histones, leading to a more compact chromatin conformation with limited access for transactivators and the suppression of transcription. HDAC mRNA and protein overexpression was observed in endometrial and ovarian cancers. Numerous in vitro studies have shown that HDAC inhibitors, through their actions on histone and nonhistone proteins, are able to reactivate the tumor suppressor genes, inhibit cell cycle progression and induce cell apoptosis in endometrial and ovarian cancer cell cultures. Results from mouse xenograft models also demonstrated the potency of HDAC inhibitors as anticancer reagents when used as single agent or in combination with classical chemotherapy drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available